Curemark Presents at the Rodman & Renshaw Global Healthcare Conference

Jun 07, 2010, 10:11 ET from Curemark, LLC

RYE, N.Y., June 7 /PRNewswire/ -- Curemark, LLC, (, a drug research and development company focused on the treatment of neurological diseases, presented at the Rodman & Renshaw 6th Annual Global Healthcare Conference, held May 16 - 18 in London.

Dr. Joan Fallon, founder and CEO, spoke May 17 on the development of Curemark's enzyme replacement therapy targeting neurological disorders and discussed the progress of the company's autism research.  CM-AT, Curemark's autism treatment, is now in Phase III clinical trials and has been granted Fast Track status by the FDA.

"The Rodman & Renshaw investment conference was an excellent occasion to highlight Curemark's science and provide an update on the momentum of our research for the many healthcare and biotech investors who attended the event," Fallon said.  

CM-AT, one of the first therapies to address the underlying physiology of autism, is based on Fallon's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, needed to produce the chemicals essential for brain function.  Curemark anticipates expanding its research program to examine its science in relation to other neurological conditions such as ADHD.


Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC